US FDA issues Form 483 to Cipla’s facility in MP

The US Food and Drug Administration (FDA) has issued Form 483 to Cipla’s manufacturing facility in Pithampur, Madhya Pradesh.

The FDA has censured the drug maker due to unclean equipment and lack of data.

This particular facility also came under the FDA once in 2018.